<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Dermatol</journal-id><journal-id journal-id-type="publisher-id">AD</journal-id><journal-title-group><journal-title>Annals of Dermatology</journal-title></journal-title-group><issn pub-type="ppub">1013-9087</issn><issn pub-type="epub">2005-3894</issn><publisher><publisher-name>Korean Dermatological Association; The Korean Society for Investigative Dermatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25473222</article-id><article-id pub-id-type="pmc">4252667</article-id><article-id pub-id-type="doi">10.5021/ad.2014.26.6.706</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Evening Primrose Oil for the Prevention of Xerotic Cheilitis in Acne Patients Being Treated with Isotretinoin: A Pilot Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Kui Young</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Ko</surname><given-names>Eun Jung</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>In Su</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Kapsok</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Beom Joon</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Seo</surname><given-names>Seong Jun</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Myeung Nam</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hong</surname><given-names>Chang Kwun</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Corresponding author: Seong Jun Seo, Department of Dermatology, Chung-Ang University Hospital, 102 Heukseok-ro, Dongjak-gu, Seoul 156-755, Korea. Tel: 82-2-6299-1525, Fax: 82-2-823-1049, <email>drseo@hanafos.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2014</year></pub-date><volume>26</volume><issue>6</issue><fpage>706</fpage><lpage>712</lpage><history><date date-type="received"><day>30</day><month>10</month><year>2013</year></date><date date-type="rev-recd"><day>14</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 The Korean Dermatological Association and The Korean Society for Investigative Dermatology</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>The most common adverse effects of oral isotretinoin are cheilitis, skin dryness, dry eyes, and conjunctivitis, whereas evening primrose oil (EPO) is known to improve skin moisture and transepidermal water loss (TEWL) in healthy adults and atopic patients.</p></sec><sec><title>Objective</title><p>To evaluate the clinical efficacy and safety of EPO in preventing xerotic cheilitis in acne patients being treated with oral isotretinoin.</p></sec><sec><title>Methods</title><p>Forty Korean volunteers of Fitzpatrick skin types III and IV, having moderate acne, were enrolled and randomized to receive either isotretinoin with or without EPO for 8 weeks. The efficacy of treatment was evaluated on the basis of global acne grading system scores, number of inflammatory and noninflammatory lesions, TEWL, corneometry, physician's global assessment, and patient satisfaction.</p></sec><sec><title>Results</title><p>The results after 8 weeks of treatment showed that the TEWL of the lip increased significantly during isotretinoin treatment, whereas the TEWL of the hand dorsum showed no significant change. The increase of the TEWL of the lip was more definite in the control group than in the experimental group. The number of acne lesions decreased significantly in both groups, and there were no differences between them.</p></sec><sec><title>Conclusion</title><p>Our study suggests that the addition of EPO improved xerotic cheilitis in acne patients being treated with oral isotretinoin. However, besides TEWL and corneometry assessments, additional studies are required for a complete understanding of the role of EPO in xerotic cheilitis in acne patients being treated with oral isotretinoin.</p></sec></abstract><kwd-group><kwd>Acne vulgaris</kwd><kwd>Evening primrose oil</kwd><kwd>Isotretinoin</kwd><kwd>Xerotic cheilitis</kwd></kwd-group><funding-group><award-group><funding-source country="KR">Ministry of Trade, Industry and Energy</funding-source><award-id>10044186</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Oral isotretinoin (13-<italic>cis</italic>-retinoic acid) was first approved as a treatment for severe acne by the US Food and Drug Administration in 1982. However, its off-label uses for cases of less severe acne have increased over time<xref rid="B1" ref-type="bibr">1</xref>. Isotretinoin exerts its therapeutic effects on acne by reducing sebum excretion and follicular keratinization, as well as reducing colonies of <italic>Propionibacterium acnes</italic>. Its effectiveness is dependent on the accumulated dose, and any treatment must be continued long enough to reach the standard accumulated dose of 120 to 150 mg/kg<xref rid="B2" ref-type="bibr">2</xref>. Although the safety profile of isotretinoin is favorable, this treatment is associated with certain reversible, dose-related adverse effects. The most common adverse effect is mucocutaneous dryness in the lips, eyes, and other epidermal surfaces. Skin dryness together with an increase in transepidermal water loss (TEWL) and erythema during treatment with isotretinoin seem to be the key factors causing patient discomfort, and these adverse effects can compromise patient compliance<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>. Therefore, managing these adverse effects and their influence on patient compliance is the key to treatment success. Evening primrose oil (EPO) contain gamma-linolenic acid (GLA, 18:3&#x003c9;6), a carboxylic acid with an 18-carbon chain and three <italic>cis</italic> double bonds.<xref rid="B6" ref-type="bibr">6</xref> It is a fatty acid found primarily in vegetable oils; it improves skin hydration in healthy adults and atopic patients<xref rid="B7" ref-type="bibr">7</xref>,<xref rid="B8" ref-type="bibr">8</xref>, and is indicated for relieving xerosis in patients undergoing therapy with oral isotretinoin. It could be hypothesized that acne patients had better compliance with isotretinoin treatment with EPO because it causes fewer mucocutaneous adverse effects such as xerotic cheilitis. In this study, we investigated the efficacy and tolerability of EPO in preventing xerotic cheilitis in acne patients being treated with oral isotretinoin.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><p>This was a prospective, randomized, and single-blind study to compare the effectiveness of EPO containing GLA as an adjuvant treatment in patients with moderate acne who are being treated with oral isotretinoin.</p><sec><title>Participants</title><p>In this study, 40 Korean subjects (23 women and 17 men) of Fitzpatrick skin types III and IV, with moderate acne (mean global acne grading system score, 24.20&#x000b1;2.71), were enrolled. This clinical study was approved by the institutional review board of Chung Ang University Hospital, Seoul, Korea (IRB No. C2011045[493]). Before enrollment, patients were informed of the study procedures, possible risks, and benefits. Signed consent was obtained from each patient. The exclusion criteria included severe acne types, such as acne conglobata or acne fulminans, history of keloid, other systemic diseases, or pregnancy and lactation. The baseline characteristics of the subjects are presented in <xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec><title>Interventions</title><p>All patients received isotretinoin at daily doses between 0.25 and 0.4 mg/kg for 8 weeks. In the experimental group, the participants simultaneously received six 450 mg EPO capsules thrice daily, providing 240 mg of GLA for 8 weeks. All participants were given a cleansing gel and moisturizer, which they were instructed to use twice a day (morning and night) throughout the study. The use of any other additional cosmetic products on the face was prohibited.</p></sec><sec><title>Assessments</title><p>Clinical evaluations consisted of assessment of acne severity, counting of facial lesions, and evaluation of the incidence of adverse effects. For the evaluation of the effect on the skin and lip, instrumental evaluations were performed on the skin of the hand dorsum and of the lower lip.</p><p>Measurements with Tewameter TM300 (Courage+Khazaka Electronic GmbH, Cologne, Germany) to quantify TEWL and with Corneometer CM 825 (Courage+Khazaka Electronic GmbH) to quantify the moisture content of the stratum corneum were taken at each clinic visit. All measurements on the lip and hand dorsum were taken in sitting position with the subject's forearm lying on the table. Measurements were always performed in the same assessment room. Room temperature (24.0&#x02103;~25.5&#x02103;) and humidity (18%~24%) were recorded before testing.</p><p>Photographic documentation by using identical camera settings, lighting, and positioning was done at each visit. A comparison evaluation of the photographs was done by two independent dermatologists by using the quartile grading scale: 1=poor (0%~25%), 2=moderate (26%~50%), 3=good (51%~75%), 4=excellent (76%~100%). The patient satisfaction score was recorded as follows: unsatisfied, slightly satisfied, satisfied, or very satisfied. Any adverse effect was recorded over the entire study period.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed with the SPSS ver. 12.0 for Windows statistical package (SPSS Inc., Chicago, IL, USA). We used the chi-square test, two-sample t-test, or Wilcoxon rank sum test for the analysis of demographic data. The two-sample t-test was used to compare the TEWL and corneometry readings between the groups. Null hypotheses of no difference were rejected if <italic>p</italic>-values were &#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Forty patients were included in this study, 20 in the experimental group and 20 in the control group, ranging in age from 18 to 31 years (<xref ref-type="table" rid="T1">Table 1</xref>). The degree of acne was decreased significantly in both groups (<italic>p</italic>&#x0003c;0.001) after 2 months of treatment. In both groups, the mean number of comedones, pustules, and papules were decreased significantly at 2 months; however, the groups did not differ significantly in terms of the number of comedones and pustules (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>The clinical evaluation of the other cutaneous symptoms except xerotic cheilitis did not differ significantly between groups, although the experimental group tended to have a lower score than the control group for dryness of the skin (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="table" rid="T3">Table 3</xref>, <xref ref-type="table" rid="T4">4</xref>). The proportion of patients presenting with xerotic cheilitis after 2 months of therapy was significantly lower in the experimental group. On the lower lip, the experimental group tended to have a lower score than the control group for TEWL, and there was a significant difference between the two groups after 8 weeks of treatment (<xref ref-type="fig" rid="F2">Fig. 2A</xref>, <xref ref-type="table" rid="T5">Table 5</xref>). Corneometry showed no significant differences between the two groups (<xref ref-type="fig" rid="F2">Fig. 2B</xref>, <xref ref-type="table" rid="T6">Table 6</xref>).</p><p>On the quartile grading scale, the mean clinical improvement for xerotic cheilitis at 8 weeks after the final treatment was 2.20&#x000b1;0.52 in the control group and 3.15&#x000b1;0.81 in the experimental group (<xref ref-type="fig" rid="F3">Fig. 3</xref>, <xref ref-type="table" rid="T7">Table 7</xref>). There were significant differences between the control and experimental groups (<italic>p</italic>&#x0003c;0.05). Concerning patient satisfaction, most of the final ratings were moderate or good in both groups, although the experimental group was significantly satisfied at week 4 (<xref ref-type="fig" rid="F4">Fig. 4</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Isotretinoin is a type of retinoid that has been widely used in the topical and systemic treatment of various dermatoses: psoriasis, keratinization disorders, keratotic genodermatosis, and severe acne. It is also used in the treatment and/or chemoprevention of skin cancer and other neoplasms. Isotretinoin inhibits sebaceous gland function and keratinization; however, its exact mechanism of action is not well understood<xref rid="B9" ref-type="bibr">9</xref>. Moreover, this drug has immunomodulator and anti-inflammatory properties<xref rid="B10" ref-type="bibr">10</xref>. Oral isotretinoin is the treatment of choice for severe inflammatory acne and is considered an alternative treatment for patients with moderate and long-term mild inflammatory acne with poor response to other treatments<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B12" ref-type="bibr">12</xref>.</p><p>The recommended dose of oral isotretinoin for acne treatment is 0.5 to 1.0 mg/kg daily for 16 to 32 weeks, reaching 120 to 150 mg/kg<xref rid="B2" ref-type="bibr">2</xref>. This regimen is well known to produce good results; however, it causes several dose-dependent adverse effects such as xerotic cheilitis, mild xerosis, and epistaxis<xref rid="B13" ref-type="bibr">13</xref>. Because of these adverse effects, some patients have difficulty in complying with the recommended dose. These mucocutaneous adverse effects mainly reflect decreased sebum production, reduced stratum corneum thickness, and altered skin barrier function<xref rid="B9" ref-type="bibr">9</xref>. Cheilitis is the most common manifestation and occurs in virtually all patients who receive isotretinoin therapy<xref rid="B14" ref-type="bibr">14</xref>. In fact, the absence of cheilitis in an apparent "treatment failure" that should raise the suspicion of noncompliance<xref rid="B15" ref-type="bibr">15</xref>. In an effort to overcome this concern, the use of hydrating and emollient products is often recommended to control the most frequent mucocutaneous adverse effects. In this study, we investigated the efficacy of oral EPO instead of a topical emollient for relieving xerotic cheilitis in patients undergoing therapy with oral isotretinoin.</p><p>The treatment groups were well matched at baseline concerning demographic data and individual isotretinoin dose; there were no significant differences between the experimental and control groups. The comparison between groups did not show significant differences in terms of the number of comedones and pustules after 8 weeks of treatment. This means that isotretinoin had an about the same curative effect for acne vulgaris in both groups. Oral EPO did not influence the efficacy of oral isotretinoin treatment. GLA inhibits inflammatory responses by regulating nuclear factor-kappaB and activator protein-1 activation, and prostaglandin E1 and 15-hydroxyeicosatrienoic acid converted from GLA have anti-inflammatory properties. For these reasons, the acne lesions were expected to improve somewhat better in the experimental group; however, the results did not show this effect.<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>,<xref rid="B18" ref-type="bibr">18</xref></p><p>The results also showed that the group with oral EPO showed lower TEWL and higher corneometry readings than the control group. These suggest that GLA might improve skin properties and protect the skin barrier. This difference can be attributed to the higher concentration of GLA in EPO that is necessary to maintain hydration<xref rid="B19" ref-type="bibr">19</xref>. Deficiencies in n-6 essential fatty acids (EFA) correlated with the severity of skin barrier dysfunction and cutaneous inflammation<xref rid="B20" ref-type="bibr">20</xref>. GLA efficiently reverses epidermal hyperproliferation owing to its metabolites such as anti-inflammatory eicosanoids that exert antiproliferative properties, and these actions are associated with an increase in ceramide synthesis and improvement of skin barrier function<xref rid="B21" ref-type="bibr">21</xref>.</p><p>The skin of the lip has many different properties compared with the hand dorsum skin. The lip does not contain hair or sweat glands and sebaceous glands. The lip skin epithelium is characterized by thin and nonkeratinized tissue and a poor water-holding capacity<xref rid="B22" ref-type="bibr">22</xref>. We detected a significantly high TEWL on the lip compared with that on the hand dorsum skin in patients treated with oral isotretinoin. The dryness and desquamation of the lip in patients treated with oral isotretinoin may be caused by the thin and low barrier function of the nonkeratinized epithelium<xref rid="B22" ref-type="bibr">22</xref>.</p><p>The human skin is rich in sebaceous glands, and the sebum excreted by these glands is primarily composed of tryglycerides, wax esters, and squalene<xref rid="B23" ref-type="bibr">23</xref>. Sebum analysis demonstrates that the major components of sebum differ from those of EFA<xref rid="B24" ref-type="bibr">24</xref>. Human skin is not able to biosynthesize GLA from the precursor linoleic acid (LA, 18:2&#x003c9;6), or arachidonic acid (20:4&#x003c9;6) from dihomogamma-linolenic acid (20:3&#x003c9;6), because of the absence of the enzymes delta 6- and delta 5-desaturase<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B25" ref-type="bibr">25</xref>. Therefore, EFA metabolites have to be synthesized in the liver and transported to the skin through the bloodstream. Because EFAs come strictly from the diet<xref rid="B24" ref-type="bibr">24</xref>, dietary supplementation with GLA-containing EPO skips the metabolic step of 6-desaturation of LA to form GLA<xref rid="B26" ref-type="bibr">26</xref>. Such a supplementation should compensate for the lack of EFA in patients treated with isotretinoin<xref rid="B27" ref-type="bibr">27</xref>.</p><p>GLA and its synthetic derivatives serve important and diverse roles in the structural maintenance and immunologic balance of the epidermis<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>. Therefore, GLA might aid in the prevention of cheilitis by the following mechanisms: (i) maintenance of the stratum corneum permeability barrier and (ii) maturation and differentiation of the stratum corneum.</p><p>According to the patients' satisfaction level, the difference in clinical efficacy against xerosis between the experimental and control groups was a peak at 4 weeks after treatment, which gradually decreased. This means that the most uncomfortable period of cheilitis is at about 4 weeks after taking isotretinoin. Thereafter, the patients adapted themselves to the xerotic change. We observed that the use of oral EPO did not influence the efficacy of oral isotretinoin treatment and improved xerotic cheilitis and the sensation of dryness. It seemed that acne patients had better compliance with the treatment with EPO because of its fewer mucocutaneous adverse effects.</p><p>EPO was found to induce an improvement in the cutaneous barrier function of the lips in acne patients taking isotretinoin, as reflected in their TEWL. The addition of EPO prevented retinoid-induced adverse effects without any complications. The statistical correlation between EPO and xerotic cheilitis is relatively weak. On the basis of these results, additional studies are required before we can have a complete understanding of the role of EPO on xerotic cheilitis in acne patients being treated with oral isotretinoin.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>This work was supported by the Infrastructure Program for New-growth Industries (10044186; Development of Smart Beauty Devices Technology and Establishment of Commercialization Support Center) funded by the Ministry of Trade, Industry and Energy (MI, Korea).</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layton</surname><given-names>A</given-names></name></person-group><article-title>The use of isotretinoin in acne</article-title><source>Dermatoendocrinol</source><year>2009</year><volume>1</volume><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">20436884</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haider</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>JC</given-names></name></person-group><article-title>Treatment of acne vulgaris</article-title><source>JAMA</source><year>2004</year><volume>292</volume><fpage>726</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">15304471</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brito Mde</surname><given-names>F</given-names></name><name><surname>SantAnna</surname><given-names>IP</given-names></name><name><surname>Galindo</surname><given-names>JC</given-names></name><name><surname>Rosendo</surname><given-names>LH</given-names></name><name><surname>Santos</surname><given-names>JB</given-names></name></person-group><article-title>Evaluation of clinical adverse effects and laboratory alterations in patients with acne vulgaris treated with oral isotretinoin</article-title><source>An Bras Dermatol</source><year>2010</year><volume>85</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">20676466</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herane</surname><given-names>MI</given-names></name><name><surname>Fuenzalida</surname><given-names>H</given-names></name><name><surname>Zegpi</surname><given-names>E</given-names></name><name><surname>De Pablo</surname><given-names>C</given-names></name><name><surname>Espadas</surname><given-names>MJ</given-names></name><name><surname>Trull&#x000e1;s</surname><given-names>C</given-names></name><etal/></person-group><article-title>Specific gel-cream as adjuvant to oral isotretinoin improved hydration and prevented TEWL increase--a double-blind, randomized, placebo-controlled study</article-title><source>J Cosmet Dermatol</source><year>2009</year><volume>8</volume><fpage>181</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">19735515</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLane</surname><given-names>J</given-names></name></person-group><article-title>Analysis of common side effects of isotretinoin</article-title><source>J Am Acad Dermatol</source><year>2001</year><volume>45</volume><fpage>S188</fpage><lpage>S194</lpage><pub-id pub-id-type="pmid">11606952</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nykiforuk</surname><given-names>CL</given-names></name><name><surname>Shewmaker</surname><given-names>C</given-names></name><name><surname>Harry</surname><given-names>I</given-names></name><name><surname>Yurchenko</surname><given-names>OP</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Reed</surname><given-names>C</given-names></name><etal/></person-group><article-title>High level accumulation of gamma linolenic acid (C18:3&#x025b3;6.9,12 cis) in transgenic safflower (Carthamus tinctorius) seeds</article-title><source>Transgenic Res</source><year>2012</year><volume>21</volume><fpage>367</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">21853296</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muggli</surname><given-names>R</given-names></name></person-group><article-title>Systemic evening primrose oil improves the biophysical skin parameters of healthy adults</article-title><source>Int J Cosmet Sci</source><year>2005</year><volume>27</volume><fpage>243</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">18492193</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senapati</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Gangopadhyay</surname><given-names>DN</given-names></name></person-group><article-title>Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2008</year><volume>74</volume><fpage>447</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">19052401</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Vahlquist</surname><given-names>A</given-names></name><name><surname>Saurat</surname><given-names>JH</given-names></name></person-group><chapter-title>Retinoid</chapter-title><person-group person-group-type="editor"><name><surname>Goldsmith</surname><given-names>LA</given-names></name><name><surname>Katz</surname><given-names>SI</given-names></name><name><surname>Gilchrest</surname><given-names>BA</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Leffell</surname><given-names>DJ</given-names></name><name><surname>Wolff</surname><given-names>K</given-names></name></person-group><source>Fitzpatrick's dermatology in general medicine</source><edition>8th ed</edition><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name><year>2012</year><fpage>2759</fpage><lpage>2766</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orfanos</surname><given-names>CE</given-names></name><name><surname>Zouboulis</surname><given-names>CC</given-names></name><name><surname>Almond-Roesler</surname><given-names>B</given-names></name><name><surname>Geilen</surname><given-names>CC</given-names></name></person-group><article-title>Current use and future potential role of retinoids in dermatology</article-title><source>Drugs</source><year>1997</year><volume>53</volume><fpage>358</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">9074840</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollnick</surname><given-names>H</given-names></name><name><surname>Cunliffe</surname><given-names>W</given-names></name><name><surname>Berson</surname><given-names>D</given-names></name><name><surname>Dreno</surname><given-names>B</given-names></name><name><surname>Finlay</surname><given-names>A</given-names></name><name><surname>Leyden</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Management of acne: a report from a Global Alliance to Improve Outcomes in Acne</article-title><source>J Am Acad Dermatol</source><year>2003</year><volume>49</volume><issue>1 Suppl</issue><fpage>S1</fpage><lpage>S37</lpage><pub-id pub-id-type="pmid">12833004</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielitz</surname><given-names>A</given-names></name><name><surname>Krautheim</surname><given-names>A</given-names></name><name><surname>Gollnick</surname><given-names>H</given-names></name></person-group><article-title>Update in retinoid therapy of acne</article-title><source>Dermatol Ther</source><year>2006</year><volume>19</volume><fpage>272</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">17014482</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunliffe</surname><given-names>WJ</given-names></name><name><surname>van</surname><given-names>de</given-names></name><name><surname>Caputo</surname><given-names>R</given-names></name><name><surname>Cavicchini</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>A</given-names></name><name><surname>Fyrand</surname><given-names>OL</given-names></name><etal/></person-group><article-title>Roaccutane treatment guidelines: results of an international survey</article-title><source>Dermatology</source><year>1997</year><volume>194</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">9252756</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>CN</given-names></name><name><surname>Krach</surname><given-names>KJ</given-names></name></person-group><article-title>Uses and complications of isotretinoin therapy</article-title><source>J Am Acad Dermatol</source><year>2001</year><volume>45</volume><fpage>S150</fpage><lpage>S157</lpage><pub-id pub-id-type="pmid">11606947</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almond-Roesler</surname><given-names>B</given-names></name><name><surname>Blume-Peytavi</surname><given-names>U</given-names></name><name><surname>Bisson</surname><given-names>S</given-names></name><name><surname>Krahn</surname><given-names>M</given-names></name><name><surname>Rohloff</surname><given-names>E</given-names></name><name><surname>Orfanos</surname><given-names>CE</given-names></name></person-group><article-title>Monitoring of isotretinoin therapy by measuring the plasma levels of isotretinoin and 4-oxo-isotretinoin. A useful tool for management of severe acne</article-title><source>Dermatology</source><year>1998</year><volume>196</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">9557257</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wauquier</surname><given-names>F</given-names></name><name><surname>Barquissau</surname><given-names>V</given-names></name><name><surname>L&#x000e9;otoing</surname><given-names>L</given-names></name><name><surname>Davicco</surname><given-names>MJ</given-names></name><name><surname>Lebecque</surname><given-names>P</given-names></name><name><surname>Mercier</surname><given-names>S</given-names></name><etal/></person-group><article-title>Borage and fish oils lifelong supplementation decreases inflammation and improves bone health in a murine model of senile osteoporosis</article-title><source>Bone</source><year>2012</year><volume>50</volume><fpage>553</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">21664309</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Yoo</surname><given-names>TH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>HY</given-names></name><name><surname>Nam</surname><given-names>BY</given-names></name><name><surname>Kwak</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy</article-title><source>Yonsei Med J</source><year>2012</year><volume>53</volume><fpage>1165</fpage><lpage>1175</lpage><pub-id pub-id-type="pmid">23074118</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CS</given-names></name><name><surname>Sun</surname><given-names>HL</given-names></name><name><surname>Lii</surname><given-names>CK</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Liu</surname><given-names>KL</given-names></name></person-group><article-title>Gamma-linolenic acid inhibits inflammatory responses by regulating NF-kappaB and AP-1 activation in lipopolysaccharide-induced RAW 264.7 macrophages</article-title><source>Inflammation</source><year>2010</year><volume>33</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19842026</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapkin</surname><given-names>RS</given-names></name><name><surname>Ziboh</surname><given-names>VA</given-names></name></person-group><article-title>Inability of skin enzyme preparations to biosynthesize arachidonic acid from linoleic acid</article-title><source>Biochem Biophys Res Commun</source><year>1984</year><volume>124</volume><fpage>784</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">6439197</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>A</given-names></name><name><surname>Ooyama</surname><given-names>K</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Kachi</surname><given-names>H</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><etal/></person-group><article-title>Dietary supplementation of gamma-linolenic acid improves skin parameters in subjects with dry skin and mild atopic dermatitis</article-title><source>J Oleo Sci</source><year>2011</year><volume>60</volume><fpage>597</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">22123240</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Seong</surname><given-names>K</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name></person-group><article-title>Gamma-linolenic acid in borage oil reverses epidermal hyperproliferation in guinea pigs</article-title><source>J Nutr</source><year>2002</year><volume>132</volume><fpage>3090</fpage><lpage>3097</lpage><pub-id pub-id-type="pmid">12368400</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H</given-names></name><name><surname>Tagami</surname><given-names>H</given-names></name></person-group><article-title>Functional properties of the surface of the vermilion border of the lips are distinct from those of the facial skin</article-title><source>Br J Dermatol</source><year>2004</year><volume>150</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">15030342</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picardo</surname><given-names>M</given-names></name><name><surname>Ottaviani</surname><given-names>M</given-names></name><name><surname>Camera</surname><given-names>E</given-names></name><name><surname>Mastrofrancesco</surname><given-names>A</given-names></name></person-group><article-title>Sebaceous gland lipids</article-title><source>Dermatoendocrinol</source><year>2009</year><volume>1</volume><fpage>68</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">20224686</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>A</given-names></name></person-group><article-title>Epidermal surface lipids</article-title><source>Dermatoendocrinol</source><year>2009</year><volume>1</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">20224687</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapkin</surname><given-names>RS</given-names></name><name><surname>Ziboh</surname><given-names>VA</given-names></name><name><surname>Marcelo</surname><given-names>CL</given-names></name><name><surname>Voorhees</surname><given-names>JJ</given-names></name></person-group><article-title>Metabolism of essential fatty acids by human epidermal enzyme preparations: evidence of chain elongation</article-title><source>J Lipid Res</source><year>1986</year><volume>27</volume><fpage>945</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">3097227</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brenner</surname><given-names>RR</given-names></name></person-group><article-title>Nutritional and hormonal factors influencing desaturation of essential fatty acids</article-title><source>Prog Lipid Res</source><year>1981</year><volume>20</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">7342101</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proksch</surname><given-names>E</given-names></name><name><surname>Holleran</surname><given-names>WM</given-names></name><name><surname>Menon</surname><given-names>GK</given-names></name><name><surname>Elias</surname><given-names>PM</given-names></name><name><surname>Feingold</surname><given-names>KR</given-names></name></person-group><article-title>Barrier function regulates epidermal lipid and DNA synthesis</article-title><source>Br J Dermatol</source><year>1993</year><volume>128</volume><fpage>473</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">8504036</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziboh</surname><given-names>VA</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Mani</surname><given-names>I</given-names></name><name><surname>Xi</surname><given-names>S</given-names></name></person-group><article-title>Biological significance of essential fatty acids/prostanoids/lipoxygenase-derived monohydroxy fatty acids in the skin</article-title><source>Arch Pharm Res</source><year>2002</year><volume>25</volume><fpage>747</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">12510822</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosche</surname><given-names>T</given-names></name><name><surname>Platt</surname><given-names>D</given-names></name></person-group><article-title>Effect of borage oil consumption on fatty acid metabolism, transepidermal water loss and skin parameters in elderly people</article-title><source>Arch Gerontol Geriatr</source><year>2000</year><volume>30</volume><fpage>139</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">15374040</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Spirt</surname><given-names>S</given-names></name><name><surname>Stahl</surname><given-names>W</given-names></name><name><surname>Tronnier</surname><given-names>H</given-names></name><name><surname>Sies</surname><given-names>H</given-names></name><name><surname>Bejot</surname><given-names>M</given-names></name><name><surname>Maurette</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Intervention with flaxseed and borage oil supplements modulates skin condition in women</article-title><source>Br J Nutr</source><year>2009</year><volume>101</volume><fpage>440</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">18761778</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>(A) Although the experimental group tended to have a lower score than the control group for dryness of the hand dorsum, transepidermal water loss (TEWL) did not show significant differences between groups. (B) On the skin of the hand dorsum, corneometry did not show significant differences between groups. EPO: evening primrose oil.</p></caption><graphic xlink:href="ad-26-706-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>(A) On the lower lip, the experimental group tended to have a lower score than the control group for transepidermal water loss (TEWL), and there was a significant difference between the two groups after 8 weeks of treatment. (B) Corneometry showed no significant differences between the two groups. EPO: evening primrose oil.</p></caption><graphic xlink:href="ad-26-706-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Clinical photographs of the lips during isotretinoin treatment. The control group (A~C) showed prominent xerotic cheilitis during the study period, and the experimental group (D~F) showed no significant cheilitis. From left: before treatment, 2 weeks later, and 8 weeks later.</p></caption><graphic xlink:href="ad-26-706-g003"/></fig><fig id="F4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Concerning patient satisfaction levels during the treatment, most of the final ratings of satisfaction were "moderate" or "good" in both groups; <sup>*</sup>however, the experimental group was "significantly satisfied" at week 4. EPO: evening primrose oil.</p></caption><graphic xlink:href="ad-26-706-g004"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Summary of demographic data</p></caption><graphic xlink:href="ad-26-706-i001"/><table-wrap-foot><fn><p>Values are presented as number (%) or mean&#x000b1;standard deviation.
EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Mean number of comedones, pustules, and papules in the two groups</p></caption><graphic xlink:href="ad-26-706-i002"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. EPO: evening primrose oil. *<italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Change of TEWL on the hand dorsum during isotretinoin treatment</p></caption><graphic xlink:href="ad-26-706-i003"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. TEWL: transepidermal water loss, EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Change in corneometry readings of the hand dorsum during isotretinoin treatment</p></caption><graphic xlink:href="ad-26-706-i004"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Change of TEWL of the lower lip during isotretinoin treatment</p></caption><graphic xlink:href="ad-26-706-i005"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. TEWL: transepidermal water loss, EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Change in corneometry readings of the lower lip during isotretinoin treatment</p></caption><graphic xlink:href="ad-26-706-i006"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Grade of clinical improvement of xerotic cheilitis by physicians</p></caption><graphic xlink:href="ad-26-706-i007"/><table-wrap-foot><fn><p>Values are presented as mean&#x000b1;standard deviation. EPO: evening primrose oil. <sup>*</sup><italic>p</italic>&#x0003c;0.05, significant.</p></fn></table-wrap-foot></table-wrap></floats-group></article>